Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Glaxo Wellcome UK Limited, Trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Zantac Tablets 150 mg.
| Pharmaceutical Form |
|---|
|
Tablet. |
Each tablet contains ranitidine 150 mg (as the hydrochloride).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ranitidine |
Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose NF Film coat: Titanium Dioxide E171 EP |
Cartons of 30, 60 or 90 tablets, in aluminium foil strips or push through double foil blister packs.
Glaxo Wellcome UK Limited, Trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
PL 10949/0042
27 March 2002
| Drug | Countries | |
|---|---|---|
| ZANTAC | Australia, Canada, Cyprus, Estonia, Hong Kong, Lithuania, New Zealand, Poland, Singapore, Turkey, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
